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ABSTRACT 
TITLE: How significant is a family history of glaucoma? Experience from 
the Glaucoma Inheritance Study in Tasmania (GIST). 
AIM: To determine the prevalence of a familial glaucoma amongst glaucoma 
sufferers in Tasmania. 
METHODS: With the cooperation of ophthalmologists, optometrists and 
pharmacists in Tasmania, patients diagnosed with glaucoma and their family 
members were identified and invited to participate in the study. All patients 
gave informed consent and a detailed questionnaire was administered. Family 
history of POAG was noted and pedigrees constructed with the help of a 
research genealogist. Each participant underwent a detailed examination, 
including visual acuity, TOP, gonioscopy, disc assessment and visual field 
testing. A score (termed the GIST score) was given to each patient which 
denotes the probability of the diagnosis of POAG being present. Subjects 
were classified as normal, suspect or POAG. Age-matched, unaffected 
participants in the Twins Eye Study in Tasmania were used as a control 
group. 
RESULTS: A total of 1702 POAG patients were identified. 1014 patients 
belonged to families in which other members were affected (familial 
glaucoma). 688 patients did not have a known family history of POAG 
(sporadic glaucoma). The size of the family groups varied from 2 to 29 
affected individuals. The patients in the familial group had higher GIST 
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scores than those in the sporadic group. Only 24% of the participants in the 
control group had a family history of glaucoma. 
CONCLUSIONS: 59.6% of POAG in Tasmania is familial. This percentage 
is higher than most previous reports of familial glaucoma and emphasises the 
importance of genetics in POAG. Patients with familial glaucoma had higher 
GIST scores, which may reflect an earlier onset and/or higher severity of 
glaucoma in the familial group. This has important implications for glaucoma 
screening and for further research in glaucoma genetics. 
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BACKGROUND 
I. INTRODUCTION 
Glaucoma is a progressive disorder of the optic nerves that is characterised by 
excavation of the optic nerve head and loss of peripheral vision. Occasionally, 
there is also loss of central vision (Alward, Fingert, Coote et al 1998; 
Quigley 1998). Glaucoma is a leading cause of irreversible blindness 
throughout the world. In the developed world, the commonest form is primary 
open angle glaucoma (POAG) (Leske 1983). 
Glaucoma is a treatable condition if detected sufficiently early in its course. 
Established optic nerve damage is irreparable, but progression to blindness 
can frequently be halted if the condition is diagnosed before this has occurred, 
usually by lowering of the intraocular pressure (Migdal and Hitchings 1986; 
Collaborative Normal-Tension Glaucoma Study Group 1998; Investigators-
The Advanced Glaucoma Intervention Study (AGIS) 2000; Kass, Heuer, 
Higginbotham et al 2002; Leske, Heijl, Hussein et al 2003). 
POAG is almost always asymptomatic in the earlier stages of the disease and 
progressive visual field loss occurs gradually; symptomatic central visual loss 
Occurs in advanced disease. It is for this reason that much of the world's 
glaucoma remains undetected, even in developed countries. Most of the large 
prevalence studies conducted to date have found that only approximately 50% 
of glaucoma cases in the community are diagnosed (Bengtsson 1981; 
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Collaborative Normal-Tension Glaucoma Study Group 1998; Investigators-
The Advanced Glaucoma Intervention Study (AGIS) 2000; Kass, Heuer et al 
2002; Leske, Heijl et al 2003). 
Blindness and visual impairment are important public health issues with 
significant socio-economic implications. Early detection and treatment of 
glaucoma represent important public health challenges throughout the world. 
No ideal screening method with suitable sensitivity and specificity has yet 
been identified. Cost-effectiveness of screening programmes for glaucoma is 
controversial (Coleman 1803; Wormald and Rauf 1995; Boivin, McGregor 
and Archer 1996; Tuck and Crick 1997). 
Since the 19th century, a family history of glaucoma has been known to be a 
risk factor for developing the condition. How great a role family history plays 
has been more difficult to elucidate. This can be explained by several factors 
and will be discussed in more detail in the following chapters. Quantifying 
family history as a risk factor may allow the development of screening 
programmes, targeting those individuals known to be at risk. 
During the last part of the 20th century, glaucoma emerged as, at least 
partially, a genetically determined disease. Several glaucoma genes have been 
identified (Alward, Fingert et al 1998; Craig and Mackey 1999; Rezaie, 
Child, Hitchings et al 2002), but these only account for a small percentage of 
glaucoma cases. There remains much yet to be understood about the 
pathogenesis of the disease. Identifying causative genes may provide 
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information about underlying disease mechanisms and lead to the 
development of targeted treatment and improved screening programs. 
The Glaucoma Inheritance Study in Tasmania (GIST) is a large-scale study 
based in Tasmania and other states in Australia. The primary aim has been to 
recruit large Australian POAG pedigrees to allow identification of POAG 
genes. This thesis discusses some of the findings of GIST and evaluates the 
role a positive family history of glaucoma plays in this population (Mackey 
2002-2003). 
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H. DEFINITION AND CLASSIFICATION OF GLAUCOMA 
Glaucoma refers to a group of diseases characterised by a progressive optic 
neuropathy, secondary to loss of retinal ganglion cells, resulting in typical 
visual field defects. 
There are several risk factors for the development Of glaucoma, but the 
pathogenesis of the disease is still, to a large extent, unknown. Elevated 
intraOcular pressure (lOP) is One of the primary risk factors and was until 
recently, considered part of the diagnosis. However, the early population 
based prevalence studies performed in the 1960's and 1970's showed a 
normal IOP in a significant number of glaucoma cases (Hollows and Graham 
1966; Leibowitz, Krueger, Maunder et al 1980) and elevated IOP is no longer 
considered a prerequisite for the diagnosis of glaucoma. Conversely, the 
Majority Of individuals With statistically elevated IOP never develop 
glaucoma (Kass, Heuer et al 2002). 
IOP nevertheless plays an inipottatit role in the management Of the disease as 
lowering of the IOP has been shown to slow the progression of optic nerve 
damage and to stabilise the vision(C011aborative Normal-Tension Glaucoma 
Study Group 1998; Investigators- The Advanced Glaucoma Intervention 
Study (AGIS) 2000; Heijl, LeSke, Betigts8Oti et al 2002; Leske, Heij1 'et al 
2003). 
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A number of schemes for the classification of glaucoma have been proposed. 
They are based on the age of the patient (infantile, juvenile, adult), the site of 
Obstruction to aqueous outflow (pre-trabecular, trabecular, post-trabecular) 
and aetiology. The most widely used is one that separates open-angle from 
closed-angle glaucoma. In open angle glaucotha, the drainage angle of the eye 
is unobstructed when examined gonioscopically. In angle closure, there is 
obstruction of the trabecular meshwork, usually by peripheral iris, impeding 
drainage of aqueous from the eye. 
The primary graticotitas, by definition, are not associated With ktiOWii OCUlat 
or systemic disorders that cause increased resistance to aqueous outflow or 
cause optic neuropathy. 
Prithary 'open angle glaucoma (POAG) is diagnosed in the presence Of 
glaucomatous optic disc damage, which may take the form of changes in the 
optic disc appearance •aiicl/Or the preSende Of .abitOrthalities in the 'visual field. 
The drainage angle is open and of normal appearance on gonioscopy (Figure 
1). It has an -adult 'Onset, in there are no SeOndak causes Of glaucoma present 
(Thomas 1994). 
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Figure 1. Gonioscopic view of normal open angle (Kanski JJ) 
Changes that may be seen in the optic disc may include the following: 
• Enlargement of the optic cup 
• Asymmetry of the cup when compared with the fellow eye 
• Narrowing of the neuroretinal rim 
• Vertical elongation of the cup 
• Regional pallor 
• Presence of a disc haemorrhage 
• A defect in the nerve fibre layer 
• Exposure of the lamina cribrosa 
• Nasal displacement of disc vessels 
• Baring of circumlinear vessels 
• Peripapillary atrophy. 
Differentiating physiological cupping from acquired glaucomatous cupping of 
the optic disc can be difficult, especially in early disease. The size of the optic 
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disc needs to be taken into account when assessing cup size (Jonas, Budde 
and Panda-Jonas 1999). Figure 2 shows characteristic optic disc changes seen 
in glaucoma. 
Figure 2. Colour photographs of right and left optic discs of a POAG patient showing 
characteristic glaucomatous changes 
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The visual field defects that occur in glaucoma corespond with nerve fibre 
bundle damage. These may include the folowing: 
• Paracentral scotoma 
• Arcuate scotoma 
• Nasal step 
• Temporal wedge 
a. 	 b. 	 C. 
d. 	 e. 
Figure 3. Examples of field defects.a) Paracentral defect, b) Superior and inferior arcuate 
defects, c)superior arcuate defect, d) advance field loss showing smal central island of vision 
remaining when 30 degree field tested, e) the same eye tested in (d) showing central 10 
degrees of field tested 
In advanced glaucoma there may be extensive loss of peripheral vision, as 
shown in Figure 3d. 
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The term "glaucoma suspect" refers to patients with findings suggestive of 
POAG but without definite evidence of established disease. 
There is still no universally accepted definition of glaucoma and the 
definitions used in different population-based studies have varied. Foster et 
al (Foster, Buhrmann, Quigley et al 2002) propose a scheme for diagnosis of 
glaucoma in population-based prevalence surveys. Cases are diagnosed on 
grounds of both structural and functional evidence of glaucomatous optic 
neuropathy. 
Leske published a review article on POAG epidemiology in1979 in which she 
states: "When all these findings (elevated IOP, characteristic optic disc 
changes and visual field loss) are present, the diagnosis is not questioned, but 
when one or two elements of the triad are missing, there is no general 
agreement as to diagnosis" (Leske and Rosenthal 1979). The Framingham 
Eye Study explored the effect of different definitions of glaucoma on the 
prevalence of the condition and on associated risk factors (Kahn and Milton 
1980). The authors concluded that the prevalence rates and strength of 
'asSodiatiOri dOuld differ aedotding to the definitions  used. This Was also 
addressed by Wolfs et al in the Rotterdam Eye Study, in which similar 
conclusions were reached (Wolfs, Borger, Ramrattan et al 2000). 
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GLAUCOMA: A FAMILIAL DISEASE 
Whilst the pathogenesis of primary open-angle glaucoma remains elusive, it 
has long been recognised that a positive family history is a risk factor for the 
disease. 
As far as we know, Benedict, in 1842, was the first to call attention to the 
familial tendencies of the disease. He reported glaucoma in "two dark-eyed 
daughters of an extremely gouty old general"(Benedict 1842). 
Alit sketchily described 3 families in 1860. In 1880, Schenkl stated "there is 
hardly an ophthalmologist who has not met with several hereditary 
cases"(Schenld 1880). Bowman added another family tree in 1865 and 
referred to glaucoma as "the most subtle of the hereditary affectations of the 
eye"(Bowman 1866). 
Von Graefe discussed the heredity of glaucoma in 1869. He emphasized the 
importance of inheritance in the aetiology of glaucoma and referred to 
families in which the disease had occurred in three or four generations but did 
not actually report pedigrees (Graefe 1869). 
It was only in the 20th century that the heredity of glaucoma began to be 
studied in more detail. Nettleship stressed the need for collection of more data 
relating to the inheritance of glaucoma in 1906 (Nettleship 1906). 
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In 1932, Julia Bell reviewed the body of knowledge regarding the heredity of 
glaucoma. She had traced glaucoma into 2 generations in 48 of 68 pedigrees 
she had collected. She wrote: "It is true that glaucoma is for the most part a 
disease of declining years and the difficulty in tracing any evidence of 
heredity is enhanced by the death of Many individuals who might have 
developed the disease had they lived longer." 
She c"ontinues:".., the age Of onset in the parents closely determines the 
period of life at which predisposed offspring will show signs of disease; 
members of a sibstrip evidently tend to bec,Orne liable at the same age"(Bell 
1932). 
In 1939, BitO Stated: "It is essential that there can be no doubt about the fact 
of heredity of glaucoma any longer and that heredity is an aetiological factor 
in glaucoma." and suggested that "healthy and affected members of families 
with hereditary glaucoma should be examined from every, and not only the 
ophthalmological point of view. The comparison Of results Of these 
examinations with those of persons suffering from non hereditary glaucoma 
Will Carry Us a great step filithet to Wards the .SOlittiOtt of the pathogenesis of 
glaucoma"(Biro 1939). 
William Stokes published a glaucoma pedigree with five affected generations 
in 1940. The type of glaucoma reported was a severe, blinding form of the 
disease with affected family members progressing to blindness in early 
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adulthood. He noted the glaucoma in this family to have been inherited in an 
autosomal dominant patern (Stokes 1940). 
The first reports Of family studies appeared in 1949. Until then, despite the 
fact that it was often stresed that heredity was an important factor in the 
pathogenesis Of glaucoma, only approximately 90 pedigrees Of families With 
glaucoma had been reported in the literature including 9 from Tasmania, 
identified by -ophthalmologist Dr Bruce Hamilton in 1938 (Hamilton 1938). 
(Figure 4). 
Figure 4. Tasmanian glaucoma pedigrees published by Dr Bruce Hamilton in 1938. 
These family trees had been presented as isolated examples, without relation 
to glaucoma as a whole, thus creating the impresion that hereditary 
glaucoma was rare and that it difered from the non-hereditary form. 
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Posner and Schlossmann reported in 1949 on a study they performed of 
glaucoma patients. Of 373 cases of primary glaucoma, 51(13.7%) had one or 
more relatives with the disease. They postulated that the hereditary group of 
glaucomas could be used as a starting point for the investigation of some of 
the more elusive problems in glaucoma, such as the pre-glaucomatous state, 
the possibility of predicting the severity of the disease and the relation 
between glaucoma and certain constitutional diseases. They reported 30 
pedigrees of glaucoma families. However, not all the pedigrees were of 
POAG, or chronic simple glaucoma as it was referred to in this paper. All 
types of glaucoma had been included, including examples of what is now 
termed angle closure glaucoma. They concluded: "It was previously shown 
that some persons are genetically glaucomatous, but show no clinical 
manifestations of the disease. They may have glaucoma at some future time 
of life, either spontaneously or as a result of a provocative factor, such as 
instillation of atropine, cataract or emotional disturbances. From this point of 
view, their normal state may be regarded as a pre-clinical stage. It would be 
interesting to find tests which would detect patients who are potentially 
glaucomatous while they are still clinically normal. 
"For a better understanding of the mode of transmission of glaucoma, it is 
essential to have a large series of good pedigrees. In most families, the 
diseaSe f011oWs a similar .COdise in the Vaiidus .affected Members. The genetic 
approach may be an aid in the early recognition of glaucoma and in the study 
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of the pie-clinical and mild phases of the disease" Welsher and SChlossnian 
1949). 
Other similar studies were conducted over the next decade and fOUnd between 
13 — 25% of relatives of glaucoma patients were affected (Waardenberg 1949; 
Biro 1951; Probert 1952; Kellerman and Posner 1955). 
However, At this stage, the classification and definition Of glaucoma Were not 
well established. Some of the studies included all types of glaucoma, and the 
Criteria for definition Of glaucoma differed in each study. In •additiOri, the 
criteria for the diagnosis of glaucoma differed from the definitions used 
today. In previous studies, there was significant emphasis placed on elevated 
In 1960, Becker, Kolker .... Roth published -a -study of relatives of known 
glaucoma patients. They included only families with chronic simple 
glaucoma in whom there Were At least two kii -OWn affected riletribeis. Siblings, 
children and parents of the affected individuals were studied. All family 
ribers Over the age Of 15 years were included. Of the 110 relatives 
examined from 24 unrelated families, 6 individuals (5.45%) met the criteria 
for recommending treatment. This figure is lower than the studies published 
until then. However, the criteria for diagnosis were strict, using an lOP of 30 
nunHg Or greater as the threshold for treatment, A value much higher than 
would be used today. Additional bias could have been introduced by the fact 
that they studied many younger family members (46% of the subjects studied 
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were under the age of 40 years), whilst all the newly diagnosed cases of 
glaucoma were found in individuals over the age of 40 years. Had they 
restricted the family members studied to those over the age of 40 years, they 
would have found approximately 10% of family members affected, which is 
consistent with previously published data (Becker, Kolker and Roth 1960). 
During the following decades, the importance of glaucoma as a preventable 
cause of blindness was recognised and efforts were made to establish 
effective methods of screening. Mass screening presents challenges as the 
diagnosis of glaucoma is based on thorough clinical examination, which is 
time-consuming and costly. In 1962, Miller and Paterson published a study 
whose aim was to determine whether thorough screening of a small selected 
population wOuld be valuable in the early diagnosis Of glaucoma sirnplex. 
Relatives of known glaucoma cases were examined. The study was divided 
into two parts: siblings between 40 and 60 years, and offspring between the 
ages of 15 and 55 years. A glaucoma-free control group was selected, and 
matched for age and sex. In the sibling group, 8.0% of the subjects had 
definite glaucoma and 38.0% were regarded as glaucoma suspects. In the 
control group, only one patient of 50 (i.e. 2.0%) was regarded as a suspect. 
This was statistically significant. 
In the offspring group, 2.7% had glaucoma, with 41.3% regarded as suspects. 
All the controls were normal. This again highlighted the hereditary nature of 
glaucoma. The authors recommended that individuals with a positive family 
history of glaucoma be regularly tested for glaucoma and that siblings of all 
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known cases of glaucoma simplex be routinely examined (Miller and 
Paterson 1962). 
In 1966, Francois and Heintz-de Bree reported on a study of the families of 
79 randomly selected glaucoma cases from their clinic. The cases were not 
from families previously known to be affected by glaucoma. 10 families did 
not meet the study criteria and were excluded. Glaucoma was found to be 
familial in 26 of the 69 families studied (37.6%), and to be inherited in an 
autosomal dominant fashion with very high penetrance. Again the criteria for 
diagnosis of glaucoma included an IOP of greater than 25 mmHg, which 
differs from our current definitions. This defutition may have selected 
pedigrees with severe disease which is strongly expressed, thus resulting in 
the high percentage of families affected (Francois and Heintz-De Bree 1966). 
Other workers including Leighton (Leighton 1968) and Perkins (Perkins 
1974) obtained similar results. Many centres began to run glaucoma family 
clinics. 
Paterson studied family members of glaucoma patients in 1961 and found 8% 
of family members were affected as compared with 0.7% in the general 
pOpulation. This increased to 10% when the subjects of were followed up 9 
years later. This figure may have been higher if all subjects had been re-
examined; 11 of the 27 subjects (40%) who had previously been classified as 
normal did not attend for a follow-up examination (Paterson 1970). All these 
studies confirmed what many ophthalmologists had suspected for years: that a 
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positive family history of POAG was risk factor for developing the disease. In 
the course of the GIST, the folowing leter was found, writen in 1973, which 
ilustrated this elegantly (Figure 5). This pedigree was not published until 
2001, after the identification of the GLC1A Gln368 STOP mutation (Craig, 
Baird, Healey eta! 2001). 
Dr DAVID WATERWORTH.: 
ra 232033 
sa °Ayr( rraeri itonwirr :coo 
24th April 1973. 
• M. 7ioe. 
174 Macquarie street. 
*Hobart. 
•Dear Gordon. 
re: Mr, I. V. W 
. 	 I know no family with a worse history of * glaucous than thin one. Their late mother had 
a bild'glaucome late in life, but I have three 
of her eons under treatment. 
One of them ( and I guess ho in the father of your Mr. I. W. W ) is Mr. Fe 3. W You saw bin at a Clinical mooting at R.H:H. he had 
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from two filtering operations, plus trauma. He 
• is going from bad to worse. 
, 	• His lower bulbar conjunctive is developing 
.a pemphigoid charectiT, and is growing over the 
lower limhus,'on,to his cornea. 	 • • 
I think you can take it the •mili has a 
very intraCtahle and. persistent glaucomm gene. - 
• -Kind regards. 
Yours sincerely. 
. 	 72. 	 • 
(D.H.waterwort1;) 
Figure 5. Leter from Dr David Waterworth, a Tasmanian ophthalmologist 
Al the above studies difer significantly in methods and in criteria for the 
diagnosis of glaucoma, resulting in diferent conclusions regarding the 
inheritance. There was a great emphasis placed on elevated IOP as part of the 
definition of glaucoma. This may have resulted in a significant number of 
cases not being detected. It was only in 1966 with the publication of the 
Ferndale Eye Study by Holows and Graham that it was realised that elevated 
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IOP was not present in all patients with glaucoma. This caused a change in 
the approach to the definition of glaucoma. Visual fields were tested by 
means of either a Bjerrum screen or Goldmann field test. These methods of 
visual field testing are considerably less sensitive than the computerised tests 
used today. The numbers of individuals in the studies were small and as 
most studies were clinic-based, which may have opened the possibility of 
selection bias related to family history and severity of disease. 
Until this stage, there was little known about the true burden of glaucoma in 
the general population and thus what role a positive family history of the 
disease played. 
During the following decades, large, population-based studies were 
conducted in several countries, which shed more light on the epidemiology 
and risk factors of the disease. 
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IV. EPIDEMIOLOGY OF PRIMARY OPEN ANGLE 
GLAUCOMA 
Epidemiology is the study of the distribution and determinants of diseases in 
human populations. It is based on the fact that disease is not randomly 
distributed throughout a population but rather that the frequency varies in 
different sub-groups. This knowledge can be used to identify features that 
cause disease. Such information is central to the design and implementation 
of intervention strategies necessary for disease prevention and treatment 
(Wilson 1990). 
It is estimated that 67.7 million people were affected by glaucoma worldwide 
in the year 2000 (Quigley 1996). Primary open angle glaucoma is the 
dothrilonest form of glaucoma in the western world (Leske 1983). It would 
not have been possible to make this estimate without well-designed, 
rigorously Concluded population based studies. These Confirmed the 
importance of glaucoma as a leading cause of preventable blindness 
throughout the world. 
The purpose of epidemiological studies of POAG is to establish the relative 
importance of disease in the population and to identify groups with high and 
low rates Of the disease. Thus, potential risk factors can bd identified and 
hypotheses formulated. Identification of risk factors has far-reaching 
preventive and therapeutic implications. Some characteristics that predict 
future glaucoma may be both causal and changeable and may therefore lend 
themselves to intervention and disease prevention strategies. Others, such as 
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age, sex, ethnicity and family history are not subject to change, but are often 
major determinants of risk and may be used to identify individuals for whom 
close medical supervision is indicated. Furthermore, factors that affect 
glaucoma risk may also predict the rate of progression of the disease. 
There are several difficulties with the design and interpretation of glaucoma 
studies. The first is that there is no universally agreed-upon definition of 
glaucoma, although recently efforts have been made to devise a standardised 
scheme for definition and diagnosis of disease (Foster, Buhrmann et al. 
2002). The definition of glaucoma has been discussed in more detail in a 
previous section. 
In many of the earlier studies of glaucoma epidemiology, methodological 
shortcomings in study design are likely to have resulted in biased estimates. 
Many of the initial prevalence studies involved populations that were self-
selected or comprised a small, non-representative segment of the total 
population. Some were based on retrospective chart reviews or blindness 
registries for a given locality. 
Incomplete case-finding can also bias results. FOr instance, studies that used 
visual field defects as a diagnostic criterion, but subjected only a proportion 
of study participants to perimetry, could under-estimate the disease 
prevalence (Wilson 1994). 
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Glaucoma is a disease with a low incidence, which necessitates large cohorts 
and long follow-up periods to obtain a sufficient number of events to ensure 
valid estimates of incidence. True population-based study designs have often 
been sacrificed in favour of targeting specific high-risk populations of ocular 
hypertensives or glaucoma relatives. 
PREVALENCE OF GLAUCOMA 
A well-designed prevalence study should have the following characteristics: 
• There should be a well-defined population to which the prevalence 
estimate corresponds. 
• Every effort should be made tO examine all the defined population or 
a specified sample of the defined population. 
• The proportion of the population that was actually examined shotild 
be reported. 
• If sampling is used, individuals sampled should be representative of 
the population with no sub-group systematically excluded from the 
examination. 
• Diagnostic criteria for glaucoma should be specified and consistently 
applied. 
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In the last few decades, numerous glaucoma prevalence studies have been 
conducted which meet these criteria (Table 1). 
Table 1. The Prevalence of Primary Open Angle Glaucoma as Reported in Prevalence 
Studies 
Study Location Age Response Prevalence 
group(years) (%) (%) 
Sweden (Bengtsson 1981) 55-69 77 0.93 
Ireland (Coffey, Reidy, Wormald et al 1993) 50+ 99.5 1.7 
Beaver Dam (Klein, Klein, Sponsel et al 1992) 43-84 83.1 2.1 
Baltimore (Tielsch, Katz, Singh et al 1991) 40+ 79.2 3.0 
Wales (Hollows and Graham 1966) 40-75 91.9 0.4 
South Africa (Salmon, Mermoud, Ivey et al 1993) 40+ 82.7 1.5 
Rotterdam (Dieletnans, Vingerling, Wolfs et al 1994) 55+ 71.0 1.0 
Casteldaccia (Giuffre, Giainmanco, Dardanoni eta! 1995) 40+ 67.3 1.2 
Barbados (Leske, Connell, Schachat et al 1994) 40-84 83.5 6.1 
Blue Mountains (Mitchell, Smith, Attebo eta! 1996) 49+ 87.9 3.0 
Melbourne (definite cases )(Wensor, McCarty, Stanislavsky 
eta! 1998) 
40-98 83 1.7 
Melbourne (definite and probable glaucoma) (Wensor, 40-98 83 2.2 
McCarty et al 1998) 
Major methodological differences between studies limit direct comparison of 
the results. 
THE EPIDEMIOLOGY OF POAG IN AUSTRALIA 
Two major population-based studies of glaucoma epidemiology have been 
conducted in Australia: the Blue Mountains Eye Study in New South Wales 
(Mitchell, Smith et at 1996) and the Melbourne Visual Impairment Project in 
Victoria (Wensor, McCarty et at 1998). 
The Blue Mountains Eye Study 
The Blue Mountains Eye Study (BMES) is a population based survey of 
vision and eye diseases in the Blue Mountn  ins region, west of Sydney 
(Mitchell, Smith et al. 1996). This urban area has a stable and homogeneous 
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population, representative of Australia for income measures and other 
measures of socio-economic status (Mitchell, Smith, Attebo et al 1995). The 
study participants were residents aged 49 years or older and were identified 
by means of a door-to-door census of the study region. Of the 4433 eligible 
persons, 3654(82.4%) participated in the study from January 1992 to January 
1994. After the potential participants who had died or had moved away from 
the area were excluded, the response rate was 87.9%, which compares 
favourably with most population-based glaucoma surveys (Table!). 
All participants underwent a detailed interview and eye examination, which 
included subjective refraction, visual field testing, applanation tonometry and 
stereo disc photography. The visual field testing component of the 
examination was conducted in two phases. In the first phase, subjects 
underwent a 300  suprathreshold visual field screening test (Humphrey 76-
point test). In the second phase a subset of participants underwent a full-
threshold Humphrey 30-2 test. 
Diagnosis of glaucoma: 
Open-angle glaucoma was diagnosed if typical glaucomatous visual field loss 
on the Humphrey 30-2 was present, combined with matching optic rim 
thinning and an enlarged cup-disc ratio (> 0.7) or cup-disc asymmetry 
between the two eyes of > 0.3. The diagnosis of open-angle glaucoma was 
excluded if gonioscopy showed signs of angle closure, rubeosis or secondary 
glaucoma, other than pseudoexfoliation. IOP was not one of the criteria used 
in the definition of glaucoma. 
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There were 3654 participants in the study. Definite or probable glaucoma was 
diagnosed in 108 participants, a prevalence of 3.0% (CI, 2.5-3.6). An 
exponential increase in prevalence was found for increasing 10-year age 
groups. The prevalence of glaucoma was 0.4% for people younger than 60 
years of age, 1.3% for people 60 to 69 years of age, 4.7% for people 70 to 79 
years of age and 11.4% for people aged 80 years or older. Women had a 
higher prevalence of glaucoma for each age group but this was of borderline 
significance after adjusting for age using logistic regression. 
51% of glaucoma cases detected were previously undiagnosed. This figure is 
remarkably similar to that found in Rotterdam (53%) (Dielemans, Vingerling 
et al 1994), Roscommon (49%) (Coffey, Reidy et al 1993) and Baltimore 
(50% amongst whites) (Sommer, Tielsch, Katz et al 1991). 
The Blue Mountains Eye Study also found that 75% of previously 
undiagnosed glaucoma cases had a presenting IOP less than 22 mmHg, which 
emphasizes the low yield likely from glaucoma screening that includes only a 
single IOP measurement. Nevertheless, the prevalence of glaucoma increased 
dramatically in patients with elevated IOP with nearly 40% of patients with 
an IOP of > 28 mmHg having glaucoma, the rise being highly significant 
(p<0.0001). This emphasises the importance of elevated IOP as a risk factor 
for the disease. 
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The Melbourne Visual Impairment Project 
The Melbourne Visual Impairment Project (Melbourne VIP) (Wensor, 
McCarty et al 1998) is a population based prevalence study of the distribution 
and determinants of eye disease in Melbourne, Australia. The participants 
were residents aged 40 or older from 9 parts of randomly selected 1986 
Australia Bureau of Statistics Census Collector Districts in Melbourne. 
Each participant underwent a standardised interview and clinical assessment, 
including visual fields and disc photographs. The diagnosis of glaucoma was 
made by a consensus panel of 6 ophthalmologists, including 2 glaucoma sub-
specialists. No specific criteria were used in the diagnosis of glaucoma.The 
final classification for each individual was decided using all available data for 
that person, including a past history of glaucoma, IOP elevated >21mmHg in 
either eye, visual field defects and optic disc changes. Each expert used his or 
her clinical judgement to classify each case in a masked fashion. Cases that 
had significant discrepancies between experts' opinions were resolved in 
open discussion. This approach was used in an attempt to overcome the 
difficulties in diagnosing glaucoma, especially in a single examination of an 
individual. 
To include institutionalised persons, residents of 13 nursing homes were 
studied. These nursing homes were randomly selected and were all located 
within 5km of a test site. Some modifications of the test procedure were 
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required because of the difficulty of testing elderly institutionalised 
individuals. The data from the nursing home group was analysed separately 
from that of the residential group because the data from the two groups were 
not directly comparable. 
In the residential group there was an 83% response rate and 3271 persons 
were examined. There were 112 (3.4%) with POAG. Of these, 56(1.7%) 
were regarded as definite, 16 (0.5%) probable and 40 (1.2%) were possible 
glaucoma sufferers. Only 28 (50%) of those with definite POAG had been 
diagnosed previously compared to 6(38%) of those with probable glaucoma 
and 8 (22%) of those with possible glaucoma. 
In the nursing home group there was a 90.6% response rate. A total of 403 
persons participated. There were 27 persons (6.7%) who were considered to 
have glaucoma. Of these, 9 persons were blind according to World Health 
Organization guidelines. 
The crude rate of POAG was higher in the nursing home group but direct 
standardization showed no significant difference in glaucoma prevalence 
between the residential (1.7%) and nursing home (2.36%) populations. The 
combined adjusted glaucoma rates for the residential and nursing home 
groups show prevalence rates of 1.7% in males and 1.91% in females older 
than 40 years of age. 
39 
The age specific prevalence of definite POAG in the Melbourne VIP was as 
follows: 0.1% for those aged 40-49, 0.6% of 50-59 year-olds, 1.9% Of 60-69 
year olds, 5.2% of 70-79 year-olds, 5.5% of 80-89 year-olds and 11.8% of 
those of 90 years or older. 
Both the BMES and Melbourne VIP confirmed the finding that POAG 
prevalence increases exponentially with advancing age. There were slight 
differences in the age-specific prevalences, which could also be attributed to 
differences in the definitions of POAG used and differences in the sample 
population. 
Nevertheless, although the large prevalence studies differ in their methods 
and in the definition used for POAG, the prevalence of POAG in 
predominantly Caucasian populations does not differ greatly. 
The population of Tasmania is largely Caucasian (Australian Bureau of 
Statistics 2001) and is likely to be similar to that found in the BMES and 
Melbourne VIP. 
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V. FAMILY HISTORY IN THE CONTEXT OF 
EPIDEMIOLOGICAL STUDIES 
Previous studies reported on the role a positive family history plays as a risk 
factor for the disease, as discussed earlier, but they were not population based 
and were subject to selection bias problems found with studies using clinic 
based ascertainment. The Baltimore Eye Survey (Tielsch, Katz, Sommer et al 
1994) provided an unbiased source of patients with POAG and controls from 
a representative sample of black and white residents of east Baltimore, 
Maryland. This population sample was used to assess the strength of the 
association between family history and POAG. Participants underwent a 
standardized examination and interview, which included questions about 
family history. Two approaches were taken in the analysis of the data. The 
first approach was to compare the family history of subjects who were 
diagnosed with POAG with those of subjects without the disease. This 
method did not control for family size. The second approach analysed the 
data from a family perspective. A data file was created that included all 
members of the families of subjects in the Baltimore Eye Survey. Statistical 
analysis was used to adjust the variance of the regression coefficients to 
account for correlation between members of the same family. 
A total of 16.1% of cases reported a positive family history of glaucoma 
amongst first-degree relatives vs 7.2% of controls. The strongest association 
was with siblings and the weakest with children. The small number of 
positive family histories reported amongst children was likely due to their 
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young age distribution in a disease whose risk, and therefore discovery, 
increases significantly later in life. 
There was clear evidence that cases' knowledge of their own diagnosis (prior 
to being diagnosed by the survey examination) was associated with the 
frequency of a positive family history. Odds ratios were 2 to 3 times higher 
for cases who knew they had glaucoma than for those whose condition was 
first diagnosed by the survey team. 
These analyses did not account for the different sizes of families for cases and 
controls. Analysis performed taking this into account showed a similar pattern 
to that found using the standard case control approach. A total of 2.13% of 
persons who were first-degree relatives of cases were reported to have a 
history of glaucoma compared with 0.92% of those who were relatives of 
controls. A history of glaucoma amongst siblings continued to demonstrate 
the strongest association with POAG, with lower associations noted for 
parents and children. Again, the association was stronger among relatives of 
those index subjects who knew they had glaucoma prior to the study 
diagnosis compared with relatives of those index subjects whose condition 
was first diagnosed by the study team. 
The Barbados Eye Study (Nemesure, Leske, He et al 1996) was based on a 
random sample of Barbados-born citizens between 40 and 84 years of age. 
The self-reported family history of OAG among 4,314 black participants was 
investigated. All participants underwent a standardised examination including 
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Humphrey perimetry, fundus photography and ophthalmic measurements. A 
comprehensive interview, which included questions on family history was 
conducted. Family members under consideration were father, mother, full and 
half- brothers and sisters, father's parents, mother's parents and sons and 
daughters. 
Participants with POAG reported a family history of glaucoma more often 
than those without glaucoma. Differences were most marked for sibling 
history. In both groups, maternal history was reported twice as frequently as 
paternal history. 
Reports of family history are probably influenced by additional reporting 
biases due to the participants prior knowledge of their own diagnosis 
(Tielsch, Katz et al 1994). This was the case in the Baltimore Eye Survey 
(BES), in which participants with a prior diagnosis of glaucoma reported a 
sibling history more than twice as often as those with newly detected OAG. 
Nevertheless, amongst participants with no such prior knowledge, those with 
newly detected OAG were about 5 times more likely to report sibling history 
than those without OAG. This finding provides convincing evidence of the 
association between OAG and sibling history since it is not influenced by 
reporting biases due to prior diagnosis. A weakness of this study was that a 
standardized OAG diagnosis was available for the BES participants, but only 
a reported glaucoma history was available for their relatives. However the 
study has the strength that unlike most family studies of diseases, it is based 
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on a cross-sectional sample of families rather than on a sample of families 
ascertained to have at least one affected individual. 
The Melbourne VIP studied the prevalence and investigated predictors of 
POAG in Victoria (Weih, Nanjan, McCarty et al 2001). This study has been 
described in detail in the section discussing the epidemiology of glaucoma. In 
multivariate logistic regression models, participants with a family history of 
glaucoma were three times more likely to have possible, probable or definite 
glaucoma. In analysis of only defmite glaucoma cases, family history was the 
only significant risk factor, other than age (OR 3.5; 95% CI, 1.9,6.7). 
The study estimated that those with a family history of glaucoma have a 
threefold increased risk of glaucoma. The authors note that the estimation of 
family history is likely to be biased by under-reporting. This will be discussed 
in more detail later in this chapter. 
The Melbourne VIP, like the Barbados Eye Study and Baltimore Eye Survey, 
found a substantial bias in reported family history between those who were 
diagnosed and undiagnosed at the time of the study. Although not statistically 
significant, a total of 29% of those with a previous diagnosis of glaucoma 
compared with 15% who were undiagnosed at the time of the study. 
This finding was consistent with results from the BMES in a paper that 
examined bias in the relationship between self-reported family history of 
glaucoma and its relationship to the prevalence of glaucoma and ocular 
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hypertension (Mitchell, Rochtchina, Lee et al 2002). A first-degree family 
history was given by 15.7% of subjects with glaucoma compared with 8.3% 
of controls, odds ratio (OR) 3.2 (95% CI 1.8- 5.6), after adjusting for 
glaucoma risk factors, including IOP. Although recall bias was evident from 
the finding of increased odds (OR 4.2) among previously diagnosed cases, the 
relationship also persisted in newly diagnosed cases (OR 2.4). 
A limitation of the studies discussed in this chapter so far is that that they 
relied on a reported family history of glaucoma, without confirming the 
diagnosis by examining the affected individuals. The body of epidemiological 
and genetic evidence suggests heredity is an important factor in the 
development of the disease. However, a more complete knowledge of the 
actual, rather than the reported familial tendency of POAG would allow a 
more accurate assessment of the magnitude of this effect. 
The Rotterdam Eye Study (Wolfs, Klaver, Ramrattan et al 1998) investigated 
the familial aggregation of POAG by examining first-degree relatives of 
glaucoma cases identified through their prevalence study, as well as a 
matched set of controls. The purpose of this study was to determine whether 
familial aggregation of glaucoma occurs in the general population and to 
determine the absolute relative risks for first-degree relatives. 
Probands were selected from the population-based Rotterdam Eye Study. 
First-degree relatives of patients with glaucoma (n=48) and control subjects 
(n=55) underwent a standardised examination, including perimetry. 
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The prevalence of glaucoma was 10.4% in siblings of glaucoma patients vs 
0.7% in siblings of controls and 1.1% in offspring of patients vs 0% in 
offspring of controls. Lifetime risk of glaucoma in relatives of patients was 
22% vs 2.3% in relatives of controls, yielding a risk ratio of glaucoma of 9.2 
(95% confidence interval= 1.2-73.9). The population attributable risk of 
glaucoma was 16.4%. 
This study had several strengths: 
• The patients and controls were selected from the same population-
based cohort, minimising selection bias 
• The investigators did not rely on history data, but actually examined 
all first-degree relatives 
• The examinations were performed in a masked fashion 
• The investigators aimed at full ascertainment and approached all 
patients with glaucoma in the source population. 
A limitation was the low number of patients, which decreased the statistical 
power of the study and created wide confidence intervals. However, the 
strength of the risk associations was strong enough to yield statistical 
significance. The participation rate in this study was relatively low, at 80% 
(Dielemans, Vingerling et al 1994), which could also introduce bias. 
This study was very thoroughly conducted and provides useful information 
but could underestimate the genetic component of glaucoma, especially if the 
children examined were too young to manifest the disease. More extensive 
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assessment of the glaucoma status in the extended family (uncles, aunts and 
cousins) may have revealed an even stronger component of familial 
aggregation. 
Inaccuracy in reported family history of disease is well-described (Kee, Tiret, 
Robo et al 1993; Aitken, Bain, Ward et al 1995). Studies of glaucoma using a 
self-reported family history may underestimate the true prevalence of 
glaucoma, which is often an asymptomatic, silent disease. A study was 
performed as part of the GIST to ascertain the prevalence of previously 
undiagnosed POAG within 5 large POAG pedigrees and to evaluate the 
reliability of a reported family history of glaucoma within these pedigrees 
(McNaught, Allen, Healey et al. 2000). The methods of the GIST are 
described in more detail in the section of this thesis entitled "Methods". 
Of the patients examined for this study, some individuals with POAG had 
been diagnosed by their ophthalmologist whilst others were diagnosed as a 
result of their participation in the research project. Family members with a 
prior diagnosis of POAG were asked to report if they were aware of any 
relatives with POAG. This reported family history was then compared to the 
actual pedigree (before the diagnosis of new cases) to calculate agreement. 
The main outcome measures were the rate of glaucoma in pedigrees and 
percentage of previously diagnosed glaucoma cases who were aware of the 
positive family history of POAG. Figure 6 shows an example of responses to 
the initial questionnaire demonstrating the discrepancies in known family 
history. 
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Figure 6. Example of the discrepancy in knowledge of family history of POAG. Two brothers 
filed in the initial GIST forms: Walter was aware of a family history, but although Reginald 
had glaucoma, he was not aware of any afected relatives. 
A total of 442 subjects from 5 pedigrees were examined. Of these, 47(11%) 
were previously diagnosed with POAG and 8 (2%) were previously 
diagnosed glaucoma suspects. As a direct result of the GIST examination 30 
cases (7%) of POAG and 41 suspects (9%)were newly diagnosed. 
Of the 47 previously diagnosed POAG cases, 41 were questioned about their 
prior knowledge of any family history and 11(27%) were unaware of their 
family history of POAG. The accuracy of reporting was highest for first-
degree relatives and lower for second-degree relatives. One of the pedigrees 
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participating in this study is a rural Victorian family found to have a GLC1A 
mutation (THER377MET) (Alward, Fingert et al. 1998). All 8 POAG patients 
questioned reported at least one affected relative. In this pedigree, the 
prevalence of glaucoma is high and the mean age of diagnosis is low (fourth 
decade of life). In contrast, another family, who has normal tension glaucoma 
that was usually diagnosed n the sixth decade of life had a lower reported 
positive family history. The overall inaccuracy of the family history 
knowledge shown by the combined pedigrees would be higher if the 
Victorian family's result were excluded from the analysis. 
No previous study has examined entire glaucoma families in such detail, 
including both affected and unaffected family members. Even within these 
large extended pedigrees, an accurately reported family history will 
underestimate the true prevalence of the disease, as a percentage of those 
thought to be unaffected are, in fact, affected. 
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VI. THE GENETICS OF PRIMARY OPEN ANGLE 
GLAUCOMA 
Although a positive family history of POAG has been recognised as a risk 
factor for centuries, it was only in the last decade that the genetics of 
glaucoma could be studied in more detail and causative genes identified. 
Medical genetics was revolutionised during the 1980's by the application of 
genetic mapping to locate the genes responsible for simple Mendelian 
diseases. Genetic mapping involves comparing the inheritance pattern of a 
trait with the inheritance pattern of chromosomal regions and allows one to 
identify the location of the gene is without knowing what it is (Lander and 
Schork 1994). 
This approach has been used for decades by experimental geneticists, but has 
only recently begun to be studied in humans. The study of human traits was 
limited by a lack of abundant supply of genetic markers with which to study 
inheritance and the inability to arrange human crosses to suit experimental 
purposes. However, Botstein and colleagues recognised that naturally 
occurring DNA sequence variation provided a virtually unlimited supply of 
genetic markers (Botstein, White, Skolnick et al 1980). With highly 
polymorphic genetic markers, one could trace inheritance in existing human 
pedigrees as if one had set up the crosses in the laboratory. This led to the 
study of rare human diseases having simple Mendelian inheritance, with 
hundreds of diseases having been genetically mapped in this fashion and 
dozens positionally cloned. 
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Most diseases and traits, however, do not follow simple inheritance patterns. 
The term "complex traits" refers to any phenotype that does not exhibit 
classic Mendelian recessive or dominant inheritance attributable to a single 
gene locus. Complexities arise when the simple correspondence between 
genotype and phenotype breaks down, either because the same gene type can 
result in different phenotypes (due to the effect of chance, environment or the 
interactions of other genes) or different genotypes can result in the same 
phenotype. 
It is often impossible to find a genetic marker that shows perfect co-
segregation with a complex trait. The reasons for this can be ascribed to a few 
basic problems. 
These include: 
• Incomplete penetrance and phenocopy 
• Genetic or locus heterogeneity 
• Polygenic inheritance 
• High frequency of disease-causing alleles 
INCOMPLETE PENETRANCE AND PHENOCOPY 
Some individuals who inherit a predisposing gene may not manifest the 
disease (incomplete penetrance), whereas others who do not inherit the gene 
nonetheless develop the disease as a result of environmental or random causes 
(phenocopy). Thus the genotype at the given locus may affect the probability 
of the disease but not fully determine the outcome. 
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GENETIC OR LOCUS HETEROGENEITY 
Mutations in any one of several genes may result in identical phenotypes. 
This hampers genetic mapping because a chromosomal region may co-
segregate with a disease in some families but not in others. 
POLYGENIC INHERITANCE 
Some traits may require the simultaneous presence of mutations in multiple 
genes. 
HIGH FREQUENCY OF DISEASE-CAUSING ALLELES 
Even a simple trait can be difficult to map if disease-causing alleles occur at a 
high frequency in the population. This becomes an even greater problem if 
genetic heterogeneity is also present. 
All of these difficulties apply to the genetics of POAG and this makes the 
identification of disease-causing genes challenging. 
By narrowing the definition of the disease or restricting the patient 
population, it is often possible to work with a trait that is more nearly 
Mendelian in its inheritance pattern and more likely to be homogeneous. This 
may apply to the clinical phenotype, the age of onset, those with a family 
history of the condition and those with more severe disease (Lander and 
Schork 1994). 
52 
There are three main approaches to identifying a disease-causing gene : 
• Candidate gene approach 
• Utilising clues from chromosomal deletions and translocations 
• Linkage analysis 
Often a combination of these techniques is used (Alward 2000). 
The candidate gene approach is useful when there is a known gene whose 
function makes it a strong suspect. 
In POAG, there are too many potential candidate genes including all the 
genes involved in the development, structure and function of the trabecular 
meshwork and optic nerve. 
By identifying patients who manifest the disease of interest and also have a 
chromosomal deletion or translocation, it is sometimes possible to show that 
the disease-causing gene is in or near the break in the chromosome. This 
technique has been used successfully in identifying genes involved in the 
developmental glaucomas such as Axenfeld-Rieger anomaly and in 
congenital glaucoma. 
Linkage studies are used in the absence of other clues as to the location and 
nature of the genes causing a disease. These studies are usually conducted on 
large families affected with the disease, looking for co-segregation between 
the disease phenotype and polymorphic genetic markers. This method usually 
requires large numbers of living affected individuals. 
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In POAG, the disease is usually of later onset which means that the parents 
and siblings of affected individuals are often deceased. Children of affected 
individuals may be too young to have manifest the disease. 
In identifying genes which cause POAG a combination of the techniques 
described above was used. In 1993, Johnson described a family with early 
onset, severe POAG (Johnson, Dracic, Kwitek et at 1993) (Figure 7). Of 59 
individuals in 5 generations who were at risk of the disease, 30 were affected. 
Figure 7. A pedigree of autosomal dominant juvenile glaucoma. Individuals affected by 
glaucoma are indicated with filled symbols. Half-filled symbols represent ocular 
hypertension. X = individuals examined by the original authors (Johnson et al, 1993). 
The phenotype in this pedigree of juvenile glaucoma resembled that of POAG 
in that the irido-corneal angle was open and the trabecular meshwork was 
normal in appearance. It differed from POAG in its early age of onset, 
autosomal dominant inheritance pattern. This led to the idea that this disease 
could serve as a model for adult-onset disease and linkage analysis was 
performed. 
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Linkage was found on the long arm of chromosome 1 (1q21- 1q31) by 
Sheffield and colleagues (Sheffield, Stone, Alward et al 1993). After this 
linkage was reported, it was confirmed in populations in the United States 
(Richards, Lichter, Boehnke et al 1994; Wiggs, Haines, Paglinauan et al 
1994) and around the world (Graff, Urbak, Jemdal et al 1995; Lichter, 
Richards, Boehnke et al 1997; Morissette, Cote, Anctil et al 1997). The 
majority of juvenile onset POAG families link to chromosome lq. A large 
family with both juvenile-onset and adult-onset POAG was also found to link 
to chromosome lq (Morissette, Cote et al 1997). 
The locus on chromosome 1 was assigned the name GLC1A. `GLC' stands 
for glaucoma, '1' stands for POAG and 'A' stands for the first linkage of the 
disease. Even though the locus had been identified, within the interval 
described there were still hundreds of genes and millions of base pairs, 
making the identification of the gene very difficult. Sunden and colleagues 
were able to narrow the interval to 3 centimorgans in 1996 (Sunden, Alward, 
Nichols et al 1996). 
At the same time as the family studies were being conducted, another group 
was working on gene expression of trabecular meshwork cells and their 
response to dexamethasone (Polanslcy, Fauss, Chen et al 1997). This was 
prompted by the fact that POAG can be induced in humans by exposure to 
corticosteroids. They determined the changes in gene expression of the 
trabecular meshwork cells exposed to dexamethasone compared to controls. 
They discovered a protein that was markedly increased when the cells were 
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exposed to corticosteroids and named the protein trabecular meshwork 
inducible glucocorticoid receptor protein (TIGR). 
The gene producing the TIGR protein was regarded as an attractive candidate 
gene for glaucoma because its expression in the trabecular meshwork and its 
response to corticosteroids. Stone et al discovered that the TIGR gene was in 
the interval containing GLC I A, further increasing the interest in this gene 
(Stone, Fingert, Alward et al 1997; Alward 2000). The gene was screened for 
mutations and was found in eight families with juvenile-onset POAG. 
Mutations have now been found in a large number of patients in populations 
around the world. 
Kubota et al (Kubota, Noda, Wang et al 1997) independently isolated the 
same protein using a subtraction strategy to isolate genes expressed in the 
retina and named it "myocilin" (gene symbol MYOC). They showed MYOC 
expression in the retina to be localised to the connecting cilium of 
photoreceptor cells. 
The HUGO Database Nomenclature Committee has adopted the term 
"myocilin" for this protein. The physiologic role of MYOC and the 
mechanisms by which mutations lead to glaucoma have yet to be elucidated. 
There is some evidence that mutations cause trabecular dysfunction (Lutjen-
Drecoll, May, Polansky et al 1998; Nguyen, Chen, Huang et a1 1998; 
Polansky and Nguyen 1998; Wilkinson, van der Straaten, Craig et al 2003) 
and reduced aqueous outflow 
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Reports have confirmed that mutations in GLC1A are responsible for 3-5% of 
adult POAG (Meyer, Bechetoille, Valtot et al 1996; Morissette, Cote et al 
1997; Alward, Fingert et al 1998; Fingert, Heon, Liebmann et al 1999). The 
overall frequency of disease-causing mutations is similar across five 
populations representing three racial groups (Fingert, Heon et al 1999). 
In 2002, Rezaie et al identified a gene responsible for autosomal dominant 
normal tension glaucoma (NTG) and designated it OPTN (for "optineurin") 
(Rezaie, Child et al 2002). They had previously mapped an adult-onset POAG 
locus (GLC1E) to chromosome 10p14-p15. It is thought that optineurin may 
play a role in neuroprotection in the optic nerve and if defective, visual loss 
and optic neuropathy typically seen in glaucoma result. 
Their initial data suggested that mutations in optineurin could be responsible 
for 16.7% of hereditary forms of normal-tension glaucoma. However, familial 
normal tension glaucoma is rare and a later study found that this mutation 
seems to be responsible for less than 0.1% of all open angle glaucoma 
(Alward, Kwon, Kawase et al 2003). 
Identification of OPTN as an adult-onset glaucoma gene provides an 
opportunity to study the biochemical pathways that may be involved in the 
pathogenesis of this group of optic neuropathies and will facilitate a shift of 
attention from the trabecular meshwork to examining factors affecting retinal 
and optic nerve head susceptibility to glaucomatous damage. 
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A number of groups have colected pedigrees with multiple afected 
individuals with adult-onset POAG in an atempt to isolate genes that could 
be relevant to this form of glaucoma. Significant linkage has been established 
in at least 4 chromosomal regions in addition to lq and 10p in families with 
POAG (Stoilova, Child, Trifan et al 1996; Wirtz, Samples, Kramer et al 1997; 
Trifan, Traboulsi, Stoilova et al 1998; Wirtz, Samples, Rust et al 1999). These 
are outlined in the Table 2. 
Table 2. Glaucoma genes and linkages identified (Craig 1999) 
Glaucoma type Locus Location Gene 
Primary open-angle glaucoma 
JOAG 8c adult-onset POAG 
POAG (adult onset) 
GLC1A 
GLC1B 
1q24.3-q25.2 
2cen-q13 
MYOC/TIGR 
NYI 
POAG (adult onset) GLC1C 3q21-q24 NYI 
POAG (intermediate onset) GLC1D 8q23 NYI 
POAG (adult onset LTG) GLC1E 10p15-p14 OPTN 
POAG GLC1F 7p35-36 NYI 
Primary congenital glaucoma 
GLC3A 2p21 CYP1B1 
GLC3B 1p36 NYI 
Developmental glaucoma 
Rieger syndrome RIEG1 
AD iris hypoplasia 4q25 PITX2 
Iridogoniodysgenesis 	 (IGD) 
syndrome 
IRID2 
Axenfeld-Rieger anomaly 
Iris hypoplasia RID1 6p25 FKHL7/ 
Familial glaucoma IGD FREAC3 
Familial glaucoma with GD 
Rieger syndrome RIEG2 13q14 NYI 
Other types 
Nail-patela syndrome NPS1 9q34 LMX1B 
Pseudoexfoliation syndrome 2p16 NYI 
Pigment 	dispersion 	syndrome 
(PDS) GPDS1 7q35-36 NYI 
PDS GPDS2 18q11-21 NYI 
NYI= not yet identified 
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At present, there is no satisfactory method available for screening the 
population for glaucoma (Wormald and Rauf 1995; Tuck and Crick 1997). 
Identifying glaucoma genes may improve our ability to detect individuals at 
risk of developing the disease and commence treatment at an earlier stage of 
the disease. Understanding the mechanisms of the disease may lead to 
improved treatment modalities. 
Presymptomatic diagnosis of at-risk individuals in pedigrees with GLC1A 
mutations is already feasible and has been performed with a high degree of 
patient acceptance in at least one large pedigree (Healey, Craig, Wilkinson et 
al 2004). Since treatment slows the progression of the disease in many cases, 
it is beneficial to diagnose patients as early as possible before irreversible 
damage has occurred. The early stages of the disease are asymptomatic and 
only half of those with the disease are diagnosed. Genetic testing allows 
targeting of individuals in a family known to be at risk, facilitating earlier 
treatment. Family members without the mutation would require less frequent 
screening, allowing better allocation of finite health resources. 
The family studied in this paper was a large pedigree of POAG which has 
been studied as part of the Glaucoma Inheritance Study in Tasmania since 
1994. The family has the MYOC mutation, THR377MET. The 72 
participants were offered the results of their DNA testing after a genetic 
counselling session. The attitudes of affected and unaffected family members 
to the use of predictive gene testing were determined by the use of a 
questionnaire. Every participant wished to know the result of the test after the 
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counselling session and 93% were happy that they had requested the result. 
96% stated they would ask for the DNA result if given the initial opportunity 
again. This study suggests that predictive glaucoma testing in appropriate 
circumstances is acceptable to patients and their families. 
Predictive DNA testing for glaucoma opens the possibility of community 
management of glaucoma by cascade screening. This would involve: 
1) identifying patients with glaucoma; 2) testing affected individuals who 
wished to be involved for MYOC mutations after counselling (and other 
glaucoma gene mutations as they are identified); 3) establishing family trees 
of individuals with suitable mutations and inviting relatives to be DNA tested; 
4) identifying new mutation carriers and if individuals are negative for the 
mutation, providing information and arranging routine population screening; 
5) entering mutation positive individuals into a standard clinical screening 
regimen for high-risk individuals; 6) treating individuals who develop early 
signs of glaucoma. 
Further research is required to determine the best regimen for clinical 
screening of high-risk individuals. The majority of POAG patients do not yet 
have an identified genetic cause and therefore predictive gene testing is not an 
option. With the identification of further genes, the risk and benefit for 
predictive DNA testing and early treatment will require further study 
(Mackey and Craig 2003). 
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When considering the cost-effectiveness of DNA testing in a population it is 
important to know what proportion of the disease is familial and therefore 
likely to be predicted by genetic testing. 
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VII. BACKGROUND OF THE GLAUCOMA 
INHERITANCE STUDY IN TASMANIA 
Population isolates are important tools in the identification of genes for 
diseases. Captive populations with a high standard of health care (ensuring a 
higher proportion of affected cases being diagnosed) and comprehensive 
genealogy records (allowing pedigrees of affected families to be identified) 
are the most suitable for genetic research. All of these characteristics apply to 
Tasmania, Australia's island state. 
Tasmania has a population of approximately 460,000 (Australian Bureau of 
Statistics 2001). European settlement began in 1803 and comprehensive 
genealogical records have been kept since this time, providing one of the best 
sets of such records in the world. Family link programs are available on the 
internet. Australia has many active genealogical societies with 1 in 30 
Australians having traced their family tree back to the original settlers. 
Family reunions are popular (Figure 8). 
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Figure 8. Photographs showing a large family from the GIST with 
pictures of the original matriarch and patriarch 
The Tasmanian population is ethnically more homogeneous than the rest of 
Australia. 91% of Tasmanians were born in Australia, the majority of these 
descended from Anglo-Celtic stock, whereas only 78% of mainland 
Australians were born here. Of the remaining Tasmanians not born in 
Australia, 5% are from the United Kingdom and 1% from the Netherlands 
(Australian Bureau of Statistics 2001). 
The Glaucoma Inheritance Study in Tasmania (GIST) was designed to utilise 
these advantages. 
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The aims of the GIST are to: 
• Identify glaucoma genes by linkage and association studies 
• Establish the frequency, phenotype and origins of genes 
• Investigate the natural history of glaucoma 
• Evaluate clinical investigations in glaucoma diagnosis 
• Evaluate presymptomatic genetic testing 
• Create a population, family and genetic database for investigation of 
new diagnostic and treatment modalities (Mackey 2002-2003) 
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METHODS 
Written informed consent was obtained from patients involved in the 
Glaucoma Inheritance Study in Tasmanian (GIST) (Appendix A), which was 
approved by the relevant ethics committees of the following institutions: The 
Royal Victorian Eye and Ear Hospital (Melbourne), The University of 
Tasmania (Hobart), and The Royal Hobart Hospital (Hobart). This study was 
conducted in accordance with the declaration of Helsinki and subsequent 
revisions. 
The identification of glaucoma cases was approached in two phases to 
maximise the number of patients detected. In the first phase, families with 
glaucoma were sought through the distribution of information leaflets placed 
in pharmacies and ophthalmology and optometry practices. The project was 
publicised through local newspapers, radio and television. 
Patients with glaucoma and their families were invited to participate in the 
GIST project. The presence of a family history was noted and in addition, 
genealogical information requesting the names of parents and grandparents 
(or even more relatives, if possible) was used in conjunction with local 
genealogical resources, such as Tasmanian Family Link 
(http://www.pioneers.tased.edu.au ). Pedigrees were constructed by the 
professional research genealogist enlisted as part of the GIST team, using 
computerised family tree databases. The second phase was to identify all 
cases of glaucoma being seen by ophthalmologists in Tasmania who had not 
been identified during the first phase of the project. 
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The Glaucoma Inheritance Study began examining families with glaucoma in 
1995. Initially, the larger families were easily identified and were the focus of 
the project. It soon became clear, however, that it was going to be more 
difficult to identify smaller families, especially as many people affected with 
glaucoma are undiagnosed and knowledge of a family history is unreliable. 
In early 1996, a 2-day conference of all GIST team members, including me, 
was held and other interested contributors were invited, including Prof Paul 
Mitchell, the principal investigator of the Blue Mountains Eye Study. During 
discussion of the above problem, he suggested that we establish a Glaucoma 
Registry for Tasmania. In 1996 I was a full-time research fellow for the study 
and became responsible for the registry's establishment and development. 
The approach to the creation of the registry was carefully considered. 
Establishing a prospective registry of volunteer patients would have been 
expensive and time-consuming and would not have served the purpose for 
which it was intended in the time frame available. At first we considered 
identifying glaucoma patients through reimbursement data from prescriptions 
filled for anti-glaucoma medications and from medicare item numbers for 
glaucoma procedures. I pointed out that whilst this would be an effective way 
of identifying numbers of patients likely to be affected by glaucoma, we 
would be unable to determine whether these patients had POAG or another 
form of glaucoma. Many glaucoma patients are one more than one 
medication so numbers of prescriptions dispensed would have been 
misleading. Stable glaucoma patients who had undergone surgery in the past 
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and were not on medication would not be captured by this approach. In 
addition, confidentiality issues would have prevented us from identifying 
patients and being able to contact them to invite them to participate in the 
study. 
In 1996, there were only 12 ophthalmologists working in the state, all of 
whom were well informed about the GIST and were collaborating with the 
GIST team. All patients diagnosed with glaucoma in the state would be under 
the care of one of the ophthalmologists; I thus concluded that the most 
inclusive way of identifying all glaucoma patients was to access them via 
each eye clinic. This also overcame difficulties with confidentiality and 
consent, as the treating ophthalmologist contacted the patients directly, 
inviting them to participate in the study. 
I performed an audit of all clinical notes held in each ophthalmologist's 
practice (well over 60,000 case histories) and cross-referenced the notes with 
all the visual field tests performed on Humphrey visual field analysers in each 
eye clinic(over 10,000 field tests). 
Each history was opened and read for characteristic comments, 
measurements, tests and treatments for glaucoma. If any were identified the 
history was read in detail. If there was evidence of glaucoma or suggestion of 
glaucoma the key patient data was transcribed to a standard proforma. Over 
approximately 1000 hours in 1996 and early 1997, I personally performed 
this data collection with minimal assistance. 
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All new glaucoma patients thus identified were contacted by their treating 
ophthalmologist and invited to participate in the study. The research 
genealogist, Maree Ring, conducted genealogy. I then reviewed pedigree 
data 
With the assistance of volunteer ophthalmologists, research fellows, 
orthoptists, nurses and medical students, large numbers of affected and 
unaffected members of extended families were examined during study field 
trips which took place in each major centre in Tasmania over weekends. 
There were five masked examiners, each of whom assessed one parameter of 
glaucoma by following the standard clinical examination protocol for each 
patient (Appendix B); one member of the research team took a history, 
obtained consent (Appendix A), refracted and measured visual acuities; 
another examined visual fields; another measured IOP and performed 
gonioscopy; and two independent ophthalmologists scored the optic discs. 
Finally, fundus photographs were taken and DNA samples collected (venous 
blood). 
In addition, several hundred elderly nursing home residents were examined 
by the GIST team, to collect a series of normal control individuals for use in 
the study. I participated in almost every field trip in 1995 and 1996 and also 
performed home visits with Associate Professor Mackey on patients unable to 
attend the clinics, representing 50 days (400 hours) of patient examinations. 
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The nursing home controls were needed primarily as a disease depleted 
control group set for genetic analysis. Although we considered using these as 
a control group for incidence of a family history of glaucoma, my analysis 
showed that they were not age matched to the total GIST population. In 
addition, many had early dementia and were unable to provide reliable details 
about a family history of glaucoma. 
It is difficult to obtain large series of individuals without glaucoma, where a 
family history of glaucoma has been questioned and cross-referenced. The 
closest comparison available to act as a control group for this study is the 
cohort from the Twins Eye Study in Tasmania, which consists of unaffected, 
age-matched twins. This data was collected to cross-reference twins with 
glaucoma pedigrees. The participants in this study have undergone a 
comprehensive ophthalmic assessment, including a family history of eye 
disease and a complete eye examination. 
Associate Professor David Mackey gave me access to the data from this 
study. I have also assisted in the clinical examination of some of the 
participants in the Twins Eye Studies. I reviewed the family history 
information sheets and compiled the data used in the control comparison. 
Information regarding a family history of glaucoma was extracted from the 
existing database. As it was not possible to examine the family members of 
the controls to confirm the diagnosis of POAG, we were forced to rely on the 
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family history as reported by the study subjects at the time of their 
assessment. 
CLINICAL ASSESSMENT 
Participants attended various eye clinics throughout Tasmania or were visited 
at their homes if they were unable to attend a clinic. A detailed questionnaire 
and a standard interview were administered (Appendix B), covering 
knowledge of family history, demographic data, medications (including drug 
names and frequency of use), and medical history of systemic disorders such 
as hypertension, diabetes, migraine, corticosteroid use and systemic vascular 
disease. Problems with vision, past eye disease or eye treatment, and ocular 
symptoms were also included. Patients were asked to bring all their 
medications or their physicians' medical summaries to the interview to 
improve the accuracy of reporting. 
A detailed eye examination was performed and included the following: 
• Subjective refraction and best corrected visual acuity using a Snellen 
chart. 
• Visual field testing. This was performed with a standard Humphrey 
automated perimeter (Humphrey, Inc, San Leandro, CA) using a 24-2 
array, a size III target, and full threshold test system. Both eyes were 
tested consecutively with a short break between each eye and using 
the appropriate near correction for 1/3 metre. The testing was 
70 
monitored by trained staff present in the room. Results were reviewed 
for reliability using fixation losses, false-positive errors, false-negative 
errors and short-term fluctuations, and defects were detected using 
pattern deviation analysis as the field needs to be adjusted for any 
shift in mean sensitivity (eg. from cataract) (Coote, McCartney, 
Wilkinson et al 1996). 
• Intraocular pressure measurement using the standard calibrated 
Goldmann applanation tonometer (Haag Streit AG, Bern, Switzerland) 
with a drop of fluorescein 2.0% tear film enhancement and topical 
local anaesthetic (Chauvin Pharmaceuticals Ltd, Essex, MC). The IOP 
was not standardised for time of day. In some patients such as those 
who were bed-hound or in geographically isolated locations, it was 
not possible to perform Goldmann tonometry. In such cases, IOP 
readings from portable devices such as Perkins (Clement Clarke, 
Harlow, Essex, UK) or Tonopen (Mentor, Norwell, MA, USA) were 
accepted as satisfactory alternatives. 
• Anterior segment examination. Any anterior chamber, iris or lens 
abnormalities were noted. 
• Gonioscopy 
• Optic disc analysis. Pupils were dilated with tropicamide 1% and 
phenylephrine 10% (Chauvin Pharmaceuticals Ltd, Essex, UK) and 
assessed using slit-lamp biomicroscopy under magnifying binocular 
stereo vision using a 78 or 90 dioptre non-contact lens or a fimdus 
contact lens. The following features were noted by two independent 
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clinicians and were ranked according to the GIST scoring system 
(Coote, McCartney et al 1996): 
a) Size of scleral canal (horizontal and vertical) 
b) Presence and amount of peripapillary changes to retinal pigment 
epithelium and choroidal vasculature 
c) Consistency and depth of retinal nerve fibre layer up to one disc 
distance from the disc edge 
d) Vascular branching pattern 
e) Presence of 'Drance' type nerve fibre layer haemorrhages 
0 Neuroretinal rim width, consistency and colour 
g) Focal defects in the rim or pits not contiguous with the central cup 
h) The vertical and horizontal cup-disc ratio as judged on contour (noting 
the phenomenon of 'overpass cupping), 'bayonetting' of emerging 
nerve head vasculature, widening of the interstices of the lamina 
cribrosa, and posterior bowing of the lamina. 
• Stereoscopic optic disc photography using a Nidek 3-Dx/F fundus camera 
(Nidek Co. Ltd, Japan) and Kodachrome ISO 64 film processed by Kodak 
(Eastman Kodak Co, Rochester, NY). Each participant had bilateral 30 
degree colour retinal stereophotographs taken centred on the optic disc 
and macula. 35 mm slide transparencies were mounted in clear plastic 
sheets, allowing close apposition of stereo pairs. 
• Optic discs were measured from stereoscopic photographs using a Pentax 
stereo viewer II (Asahi Optical Co. Ltd, Japan). All optic discs or high-
quality stereophotographs of the discs were scored independently by at 
least two glaucoma specialists based upon the GIST score protocol 
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(Coote, McCartney et al 1996). If there was disagreement, a consensus 
between the ophthalmologists was reached. 
• Venesection. Venous blood was obtained for DNA extraction. 
Patients with any signs other forms of glaucoma, trauma, inflammation, 
pseudoexfoliation, pigment dispersion, angle dysgenesis or other significant 
anterior segment pathology, or of occluded or potentially occludable angles 
on gonioscopy were excluded from the study. Other exclusion criteria were 
the presence of a field defect caused by a condition other than POAG eg. 
macular degeneration or vascular/thrombotic events, and optic disc pathology 
eg. optic disc drusen. 
DEFINITION AND CLASSIFICATION OF GLAUCOMA AND THE GIST 
SCORING SYSTEM (Coote, McCartney et al 1996). 
As discussed in the introductory chapter, the diagnosis of glaucoma can be 
difficult and the classification for research purposes can be contentious. The 
diagnosis generally takes into account the level of IOP, the optic disc 
appearance and the visual field. Previous genetic linkage studies on juvenile 
open angle glaucoma pedigrees have relied upon an analysis of definitely 
affected individual using the 'single best diagnosis' convention. Studies of 
adult-onset POAG have been complicated by limited numbers of 
unequivocally affected members identified even in very large pedigrees due 
to the later onset of the disease. Many members of the pedigree may have 
equivocal clinical features or be too young to show signs of the disease. 
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A scoring system was thus developed for this study, both to define the criteria 
to be used to diagnose glaucoma and to adjust for age. 
The GIST score was developed to facilitate the study of families with 
glaucoma. It is a numeric value between 0 and 1, where 0 is clinical certainty 
of absence of the disease and 1 is the definitive diagnosis of POAG. 
The score is sequentially developed. The first part is the clinical examination 
and assigning a value to these findings which contribute to the raw score. 
This is followed by the translation of the "raw score" into the pedigree 
probability or the GIST score which includes a component of probability of 
unaffected status. 
Clinical features that are consistent with glaucoma are scored based on a 
point system, with a maximal possible raw score of 5. One point is available 
from the IOP and one from the visual field; two points are available from the 
appearance of the optic disc. In any of these categories, one additional point is 
available for a feature highly consistent with and typical of the pedigree 
pattern. Only one additional point may be awarded per individual, giving a 
maximal raw score of 5. Those members of the pedigree who demonstrate no 
clinical evidence of glaucoma have a raw score of 0. 
The scoring system assumes autosomal dominant tiansmission. Thus, first-
degree relatives of affected individuals are assumed to have a 50% risk of 
inheriting the trait. To convert to the fmal GIST score each point of the raw 
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score increases the GIST score by 0.1. Members of the pedigree are given a 
starting probability of 0.5 in the GIST score, which reflects this risk. 
Therefore, each point of the raw score raises the GIST score from 0.5 to a 
maximum score of 1. The score is developed for the individual, not for each 
eye separately. The eye with the highest raw score is used in the development 
of the GIST score. When the raw score is 0, the GIST score is decreased by 
units of 0.1 depending on the age of the individual and the age of onset of 
disease in that pedigree. The minimum GIST score is 0. 
Development of the raw score 
• Intraocular pressure: Elevated IOP score > 22 mmHg 1 point. Grossly 
elevated IOP (>4 standard deviations above the mean ie. 28 mmHg or 
higher) may score the additional point. 
• Optic disc analysis: Optic disc changes suggestive of glaucoma score 
1 point and changes highly suggestive score 2 points. Changes 
considered as highly consistent with the pedigree may score the 
additional point (total 3). 
• Visual field: Reliability indices are taken into account. The field 
scores 0 if it is normal or if there is a defect not considered significant 
for glaucoma. There is a score of 1 for a significant field defect 
consistent with glaucoma or if markedly degraded and consistent with 
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glaucoma. An additional point can be allocated if the defect is 
especially consistent with the pedigree or with the disc appearance. 
Conversion to the GIST score 
To convert to a GIST score, each point of the raw score increases the GIST 
score by 0.1 to a maximum score of 1. If the raw score is zero, then the GIST 
score is decreased by units of 0.1 depending on the age of the individual and 
the age of onset of disease in that pedigree. 
Definition of POAG 
For the purposes of this study, individuals with a GIST score of 0.5 or lower 
were regarded as normal or unaffected, whilst those with a score of 0.7 or 
higher were regarded as POAG cases. 
Those with a GIST score of 0.6 were regarded as glaucoma suspects. 
To a limited extent, the GIST score correlates positively with the severity 
level of glaucoma in a given individual. 
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DATA MANAGEMENT & STATISTICAL ANALYSIS 
All data were entered into a password-verified Microsoft Access database. 
Microsoft Excel was used for tabulations and graphics. Statistical analyses 
were performed using the SPSS statistical package version 10 (SPSS Inc., 
Chicago, USA). If there was at least one other affected family member 
confirmed on clinical examination, the individual was classified as having 
familial glaucoma. If there was no known family history of glaucoma, the 
individual was classified as having sporadic glaucoma. The data were 
stratified by GIST scores in the familial and sporadic glaucoma groups, and 
by closest degrees of relatives with POAG in the familial glaucoma group. 
"Degree" of relationship to known glaucoma sufferers was identified on a 
four level categorisation. 
First-degree relatives are father, mother, son, daughter, and siblings. Second-
degree relatives are grandparents, grandson, granddaughter, aunt, uncle, 
nephew and niece. Third-degree relatives are first cousins, great-
grandparents, great aunt/uncle, great grandson or great granddaughter. 
Fourth-degree relatives are more distant relatives, including second cousins' 
children and great great grandparents. 
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RESULTS 
The Glaucoma Inheritance Study in Tasmania is an ongoing study whose 
database is continually updated. The results reported in this thesis are derived 
from the database as it existed in December 1999. 
Invitations were sent to 3800 patients and family members who had been 
investigated or treated for glaucoma as identified via the clinical notes of all 
ophthalmic practices in Tasmania over the preceding 15 years. A team of 
researchers examined the patients in the Glaucoma Inheritance Study, and 
their relatives. Most participants were seen on average for 2 occasions. A 
total of 2444 patients were examined. If a patient did not meet the criteria for 
the diagnosis of glaucoma then they were not included in the study. This left 
1702 glaucoma cases. 
With the assistance of a professional research genealogist using computerised 
family tree databases available in Tasmania, 309 pedigrees were constructed. 
A total of 2444 subjects were examined, from which 1702 POAG patients 
were identified (GIST score of > 0.7). 
1014 patients belonged to families in which other members were affected 
(familial glaucoma). 
688 patients did not have any family members known to be affected (sporadic 
glaucoma) (Figure 9). 
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486 individuals were assigned a GIST score of 0.6 and were classified as 
glaucoma suspects. 
From these results it can be concluded that in Tasmania 59.6% of POAG is 
familial. 
Figure 9. Bar graph showing distribution of cases between the two groups 
In the control group taken from the Twins Eye Study in Tasmania, of 155 
pairs of twins studied, 38 (24%) had a family history of glaucoma (1 st — 4 th 
degree relative affected). 
9% had a first-degree relative, 13% a second-degree relative and 2% a third-
degree relative affected. 
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PEDIGREES 
The largest pedigrees identified by the study are included on the folowing 
pages. 
KEY: 
O 	 Male 
0 	 Female 
• • Affected with glaucoma 
[2] 0 Deceased individuals 
Possibly afected 
Partialy filed boxes are glaucoma suspects 
The number of glaucoma afected individuals within pedigrees varied from 2 
to 29. There were 3 pedigrees containing 20-29 afected members, 3 
pedigrees containing 10-19 afected members, and 301 pedigrees with fewer 
than 10 afected members. Only those family members who underwent 
clinical assessment were included, so the size of the pedigrees may have been 
larger, had every family member been examined. 
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GENDER 
There was no statistically significant difference in gender distribution in the 
familial group compared with the sporadic group (chi-square value 0.14) 
(p= 0.7078) (Figure 10). 
Figure 10. Bar graph showing gender distributions between the two groups 
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Within the familial group there was no statisticaly significant diference in 
the gender distribution when assessed according to the degree of the 
relationship (Figure 11). 
Figure 11. Gender distribution by relationship in familial group 
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Median age categorised by GIST score for familial and sporadic groups 
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AGE 
Compared to the familial group, the sporadic POAG group was statisticaly 
significantly older at the age of examination by the study: 70.6 + 12.6 years 
vs 72.6 + 10.3 years (p= 0.001) and at the age of diagnosis: 61.4 +13.0 years 
vs 64.0 + 12.6 years (p<0.001) (Figure 12). 
Figure 12. Bar graph showing age distributions between the two groups 
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Distribution of relationship of affected family members 
RELATIONSHIP 
Those with familial glaucoma were stratified according to the degree of the 
relationship of the affected relatives (Figure 13). The closest known affected 
relative was: 
• a first-degree relative in 658 cases (64.9%) 
• a second-degree relative in 110 (10.8%) 
• a third-degree relative in 103 (10.2%) 
• a fourth-degree relative in 143 (14.1%) 
Figure 13. Bar graph showing distribution of relationships amongst familial group 
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GIST SCORES 
A higher GIST score reflects more advanced disease. The familial glaucoma 
group appeared to have a greater proportion of subjects with a GIST score of 
0.9 or 1.0 (38.16%) compared with the sporadic group (24.8%) (Figure 14). 
The Chi square test revealed a significant difference in the distribution of 
GIST scores between familial and sporadic cases of glaucoma (p<0.0002). 
This may reflect an earlier onset of and/or increased severity of the glaucoma 
found in the familial group. 
Figure 14. Distribution of GIST scores for familial and sporadic groups 
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DISCUSSION 
The fmding that almost 60% of POAG patients in Tasmania have at 
least one other family member affected is a higher percentage than that 
reported in most other studies (Charliat, Jolly and Blanchard 1994; 
Tielsch, Katz et al 1994; Wolfs, Klaver et al 1998; Mitchell, Rochtchina 
et al 2002). 
Familial aggregation studies of POAG are subject to several possible 
biases. Clinic-based studies tend to report a higher prevalence of 
glaucoma in relatives than in population-based studies, owing to a 
possible differential use of eye care services by family members. 
Population-based studies create smaller sample sizes and thus decreased 
statistical power (Tielsch, Katz et al 1994; Wolfs, Klaver et al 1998). 
Most previously published studies, (Tielsch, Katz et al 1994; Nemesure, 
Leske et al 1996; Mitchell, Rochtchina et al 2002) with the exception of 
the Rotterdam Eye Study (Wolfs, Klaver et al 1998) have relied on 
family history ascertained by interview rather than examination. This 
raises the possibility of recall bias and also the variability of diagnostic 
criteria when diagnosing glaucoma. In addition, the participation rates 
for population-based prevalence studies have been variable, with some 
as low as 67% (Leibowitz, Krueger et al 1980) or 71% (Dielemans, 
Vingerling et al 1994). Many studies have only considered first-degree 
relatives and not more distantly related family members. This results in 
a likely under-estimation of the familial/genetic nature of glaucoma. 
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This study has several strengths: 
• To the author's knowledge, it is the largest study of its kind reported. 
• Whilst there was a clinic-based component to the study, the initial 
point of contact with patients was through several sources, including 
pharmacies, optometrists and their treating ophthalmologist as well as 
via community advertising through the media. Tasmania has a captive 
population and it is believed that almost all diagnosed glaucoma 
patients were identified and invited to participate. This study is not 
strictly a population-based study, but owing to the nature of the island 
and to the large numbers of participants, the sample is likely to have 
included a large proportion of the population. Even population-based 
studies have inherent difficulties and participation rates in most 
studies have varied from 67% to 83% (Leibowitz, Krueger et al 1980; 
Klein, Klein et al 1992; Dielemans, Vingerling et al 1994; Tielsch, 
Katz et al 1994; Mitchell, Smith et al 1996; Wensor, McCarty et al 
1998). 
• All relatives of probands were invited to participate and relatives more 
distant than just first-degree relatives were examined. This has added 
strength to the evidence that POAG is a familial disease and added 
information about the pattern of disease in the extended family. 
• The study was performed over 6 years, which could have resulted in a 
higher number of patients and family members having been identified 
and possibly a higher number of previously undiagnosed cases being 
detected. In the Australian population, 50% of POAG cases remain 
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undiagnosed in the community (Mitchell, Smith et al 1996; Wensor, 
McCarty et at 1998). As result of the GIST being conducted over the 
last decade, a higher number of previously undiagnosed cases have 
been detected (McNaught, Allen et at 2000). This adds strength to the 
results. 
• All the patients with familial glaucoma and family members were 
examined in a masked fashion and classified according to strictly 
defined criteria. Only patients who had been examined according to 
the study protocol were included in the database. This overcomes the 
difficulties with the inaccuracies of recall of a family history or the 
possibility of incorrect diagnosis, as well as ensuring uniformity of 
diagnosis. The difficulty of ascertainment had been overcome as the 
glaucoma cases included have definite glaucoma according to strictly 
defined criteria. The majority of relatives of apparently sporadic cases 
were not examined, nor were relatives of controls. The fact that this 
may introduce ascertainment bias described in other studies 
(Nemesure, Leske et al 1996; Mitchell, Rochtchina et al 2002) is 
acknowledged but could not be overcome in this setting with limited 
time, funding and resources. 
• The number of glaucoma cases detected in Tasmania in this study 
correlates well with population-based projected numbers. The 
population of Tasmania does not differ greatly in its demographics 
from that of the population included in the Blue Mountains Eye Study 
(Australian Bureau of Statistics 2001) on the prevalence of glaucoma 
found in the Blue Mountains Eye Study and the Tasmanian Census 
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Population Data, the number of glaucoma cases likely in Tasmania 
was projected, as shown in the Table below (Prof Paul Mitchell 
personal correspondence). This study found a total of 1702 POAG 
affected individuals, which approximates the calculated projections. 
Table 3. Projections of number of glaucoma cases in Tasmania 
It is possible that factors could increase the prevalence of glaucoma in 
Tasmania, such as a large founder effect, and the fact that islands tend 
to reduce travel and result in a captive population. The data in above 
table suggest that the prevalence of glaucoma in Tasmania is 
comparable to that in the rest of Australia. 
Owing to the inherent difficulties in performing such a study, we may 
never obtain an exact estimate of the familial prevalence of the disease. 
However, to the author's knowledge, this is the largest study of this 
nature published to date and many potential biases have been overcome. 
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The results show that we may have previously underestimated the 
familial nature of the disease. 
A potential criticism of this study is the inclusion of IOP as one of the 
criteria used in the GIST score to determine the probability of the 
presence of glaucoma. It is acknowledged that this is not favoured by 
epidemiologists, but considerable controversy regarding the definition 
of glaucoma in epidemiological studies remains (Wolfs, 2000 Foster, 
2002). Optic disc abnormalities are regarded as the gold standard for 
glaucoma diagnosis in epidemiological studies but the cut-off points for 
the definition of pathological disc cupping are yet to be fully elucidated, 
differ in different racial groups, are influenced by optic disc size and 
may also depend on the modality of disc imaging used. In a recent 
paper by Foster and co-authors discussing the definition and 
classification of glaucoma in prevalence surveys, IOP was not excluded 
as a diagnostic criterion in all circumstances, with allowance made for 
an IOP exceeding the 99•5 th percentile to be used as a diagnosis of 
glaucoma in the presence of a media opacity precluding the 
examination of the optic disc and the performance of a visual field test 
(Foster, 2002). The 'expert panel' that graded glaucoma cases in the 
Melbourne VIP was given information about elevated IOP when 
making a diagnosis (Wensor, McCarty et al, 1998). 
The GIST is a genetic study rather than a purely epidemiological 
survey. In myocilin pedigrees, raised IOP is a feature of the 
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glaucomatous disease process and is one of the earliest signs of the 
onset of the disease (Fingert 2002). In using the GIST score, those 
patients with only slightly elevated IOP in the absence of glaucomatous 
disc cupping or a glaucomatous field defect would not be classified as 
having defmite glaucoma. Only those with markedly elevated IOP (>28 
mmHg) would be classified as such and it could be argued that these 
individuals are at extremely high risk of developing glaucoma, 
especially in the presence of a family history of the disease, thus 
justifying their inclusion. This is borne out by results of the BMES, 
which found that 39% of subjects with an IOP > 28 mmHg had 
glaucoma (Mitchell, Smith et al 1996). 
Blindness and visual impairment cause significant morbidity and 
premature mortality in the population. There are well-established 
correlations between visual impairment and higher risk of falls, hip 
fractures, motor vehicle accidents and depression. The risk of death is 
increased almost three-fold for those over the age of 40 with visual 
impairment. The health costs of treating eye disease are high: AU$1.8 
billion in 2004 in Australia. Glaucoma accounts for 3% of visual 
impairment and 14% of blindness in this country (Access Economics 
2004). 
The best prognosis for treatment of glaucoma relies on early detection. 
Whilst great advances in genetic testing for glaucoma have taken place 
in the last decade, with genetic testing available for some individuals, 
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there is still a lack of biochemical and genetic markers for the disease in 
most cases. Clinical examination is the only method of early detection. 
This study confirms that those with a family history of the disease are at 
a greatly increased risk of developing glaucoma and suggests that 
familial forms of disease may be more severe. 
Whilst the GIST score was developed as a research tool to assign 
probability of POAG in individuals in pedigrees of disease, it does also 
reflect disease severity, with a higher score correlating with more 
advanced disease. The distribution of patients with higher GIST scores 
appears to differ between the familial and sporadic groups, with a 
greater proportion of patients in the familial group having higher scores. 
This trend requires further research before it can be confirmed, but it 
does have important implications. The glaucoma patients with more 
advanced disease may be at higher risk of developing significant visual 
impairment or progressing to blindness. Since research has confirmed 
that even in advanced glaucoma, IOP lowering treatment is effective at 
slowing the progression of visual loss (Investigators- The Advanced 
Glaucoma Intervention Study (AGIS) 2000), it is important that those 
most at risk of blindness are identified in our community. As discussed 
in the introductory section, 50% of glaucoma remains undetected in the 
Australian population (Mitchell, Smith et al 1996; Wensor, McCarty et 
al 1998) and screening for glaucoma remains problematic. It is already 
known that a family history of glaucoma is a significant risk factor for 
developing the disease, but if we can identify those individuals at 
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greater risk of blindness through targeted case detection, it may be 
possible to reduce the impact on the community of blindness from 
glaucoma. 
In the absence of proven, cost-effective population screening for 
glaucoma, it is appropriate to recommend regular examination of those 
at risk. Public awareness and education about glaucoma should be 
increased emphasising that the disease is frequently familial and that 
whilst it is potentially blinding it is treatable. Health care professionals 
should be educated regarding the significance of a family history of 
glaucoma and refer those at risk for regular assessment. POAG patients 
should be told to encourage other family members over the age of 40 to 
undergo regular eye examinations with an appropriately trained 
professional. 
Mitchell and co-workers found a strong association between inhaled 
corticosteroid use and the presence of either glaucoma or elevated IOP 
(odds ratio 2.6%, confidence interval, 1.2-5.8) in individuals with a 
family history of glaucoma (Mitchell, Cumming and Mackey 1999). 
This suggests that taking a family history of glaucoma might form a 
valuable component of the workup of patients being considered for 
corticosteroid therapy and that corticosteroids should be used with great 
caution in persons reporting a family history of glaucoma. These 
patients need review by an ophthalmologist for the duration of the 
corticosteroid treatment and thereafter, as steroid responders have been 
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found to have an increased risk of subsequent glaucoma (Kitazawa and 
Hone 1981; Lewis, Priddy, Judd et al 1988). In the future, it might be 
feasible to perform tests for mutations in myocilin, or other glaucoma 
genes, as they become implicated, on patients before initiating 
corticosteroid treatment. 
Glaucoma is an asymptomatic disease and difficult to diagnose in its 
early stages. As it emerges as a familial/ genetic disease, the possibility 
of DNA testing to identify individuals at risk is increasingly becoming a 
reality. Knowledge of glaucoma genetics is improving rapidly and 
views about genetic testing are likely to change correspondingly. At 
present, the currently identified glaucoma gene mutations are not 
common enough to justify DNA testing in the wider community 
(Mackey and Craig 2003). However, effective predictive testing for 
myocilin glaucoma has already been performed within a large 
Australian family, with a high level of acceptability (Healey, Craig et al 
2004). 
In a study by Craig and co-workers (Craig, Baird et al 2001) 
investigating the phenotype and age-related penetrance of POAG in 
Australian families with the most common Myocilin mutation 
(G1n368STOP), 7 of the 8 pedigrees studied contained one or more 
individuals with POAG who did not carry the mutation. This implies 
that other genes remain to be found in these large families as well as in 
the smaller pedigrees and sporadic cases. 
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Predictive DNA testing opens the possibility of community 
management of glaucoma by cascade genetic screening as discussed in 
the introductory section on glaucoma genetics. Further research is 
required to determine the best regimen for clinical screening of high-
risk individuals and the most beneficial timing and methods of 
intervention. This is particularly relevant because glaucoma is an 
imminently treatable condition. At present, the majority of glaucoma 
patients do not yet have an identified genetic cause, with only about 5% 
of POAG being associated with an identified mutation (Stone, Fingert 
et al 1997). As further knowledge of the genetics of POAG is gained, 
more extensive genetic testing may become available. 
Thorough data collection was possible in the GIST because it involved 
a relatively small population; however, conclusions from this study can 
be applied to much larger communities. The rate of diagnosis of 
glaucoma can be increased by asking individuals affected with POAG 
to find out if other family members are also affected. Taking a family 
history does not end with the first consultation but should be discussed 
at follow-up consultations. Those with POAG should also inform all 
their relatives that those family members over the age of 40 years (or 
younger if the age of onset of disease was earlier) should be examined. 
The results of this study show that the familial nature of glaucoma is 
even greater than previously thought. At present there is substantial 
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impetus from government and heath care organisations to target the 
issue of blindness in the community and to improve detection and 
treatment of blinding disease. Public authorities should inform the 
general population that people with a positive family history of POAG 
should be screened for the disease. The results of this study could be 
helpful in the calculation of effectiveness and cost implications of 
disease detection in the Australian community. 
120 
CONCLUSIONS 
The finding that almost 60% of POAG patients in Tasmania have at 
least one other family member affected is higher than previously 
reported. 
This emphasizes the genetic nature of the disease and offers further 
evidence that as knowledge about the genetics of glaucoma increases, 
there will be an opportunity to apply this in the management of the 
disease. 
The findings of this study offer opportunities to improve glaucoma case 
detection in the community. Of the 1702 glaucoma patients identified 
and examined in this study, 38% had a first-degree relative affected, 
with a smaller percentage having a more distantly related family 
member with the disease. This highlights the importance of ascertaining 
a family history of glaucoma. Identifying individuals at risk will allow 
early detection of the condition. This directly influences outcome, as the 
treatment of the disease is aimed at slowing the rate of progression of 
visual loss. Damage that has already occurred as a result of the optic 
neuropathy cannot be reversed. The evidence of an association with 
family history of glaucoma, use of inhaled corticosteroids and risk of 
the disease found by Mitchell, Cumming and Mackey (Mitchell, 
Cumming et al. 1999) is another example of how important it is for all 
clinicians and patients to be aware of the significance of a family 
history of POAG. 
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Initiatives to improve eye health in the community and prevent 
blindness should aim to improve awareness of POAG in the general 
population and health care providers. Education campaigns should 
highlight the familial nature of the disease and provision made for 
resources to be made available for the assessment of those at risk. 
The identification of numerous pedigrees affected with glaucoma offers 
the possibility of identification of hitherto undiscovered genes and 
eventually possible genetic screening, either of those at risk or even a 
general population screening programme. Genetic screening in a family 
with a severe form of POAG associated with the MYOC gene has 
already been effectively performed with high acceptance from the 
family members demonstrating that there is already a role for genetic 
screening in appropriate circumstances. 
Before genetic screening can be more widely applied, more research 
will be required to investigate the frequency, phenotype and origins of 
genes, the natural history of glaucoma in affected pedigrees and the 
nature genotype- phenotype interactions. 
The cost-effectiveness of genetics screening will need to be'weighed 
against the cost of conventional screening and the benefits of early 
treatment considered. In addition to clinical evidence of the value of 
predictive gene testing it is incumbent on those working in the field to 
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evaluate the acceptability of testing to patients and family members 
(Mackey and Craig 2003). Issues relating to insurance, ethics and 
confidentiality need to be taken into consideration (Mackey, Heon and 
Webster 2003). 
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GIST 	 Glaucoma Inheritance Study in Tasmania a 
University of Tasmania, 
Eye Department, Royal Hobart Hospital 
Liverpool St, HOBART Tas 7000 
Ph & Fax 03 62 22 8553 
12 January 2000 
Dear Sir/Madam, 
colaborative project of the 
University of Melbourne, 
Department of Ophthalmology 
Royal Victorian Eye & Ear 
Hospital 
32 Gisborne St 
EAST MELBOURNE Vic 
3002 
Ph 03) 9929 8713 
As you may be aware, researchers with the University of Tasmania and the University of Melbourne 
have been part of an international colaborative efort that discovered the first gene that causes inherited 
glaucoma. Dr David Mackey and his research team in the Glaucoma Inheritance Study in Tasmania 
(GIST) are investigating many families, in Tasmania and elsewhere in Australia, with glaucoma in order 
to discover other glaucoma genes. This means in the future it may be possible to predict those family 
members at risk for glaucoma. Thus this work should benefit future generations. 
We believe that you have not yet been approached by the study, but that you may be interested in 
participating. You are under no obligation to participate in this project. If you do not wish to 
participate please indicate on the form over the page, or if you are interested please fil in the personal 
information sheet, and the family history information sheet A copy of the consent form for DNA 
testing is on the reverse of this page. If you chose to participate then we wil ask you to sign a copy of 
this and provide a sample of blood or if you prefer a mouth swab, which can be posted. 
If you would like to be involved in the study please indicate on the page over and we wil arrange 
another time to see you (usualy at your eye clinic). There is no charge for the DNA test which wil 
involve around twenty minutes of your time. Alternatively we can post you a swab kit to brush the 
inside of your cheek and post this back to us. 
If you would like further information or would like to contact us, please telephone Sue Stanwix on 6222 
8553. 
Thank you very much for your assistance. 
Yours Sincerely, 
Dr David Mackey 
on behalf of the Glaucoma Inheritance Study (GIST). 
Please tear of and keep this yelow page 	 Continued over page 
GIST Glaucoma Inheritance Study in Tasmania 
a colaborative project of the 
University of Tasmania, 
Eye Department, Royal Hobart Hospital 
Liverpool St, 
HOBART Tas 7000 
Ph & Fax 03) 6222 8553 
CONSENT FOR DNA TESTING 
Information for patients in the Glaucoma Inheritance Study in Tasmania (GIST). 
University of Melbourne, 
Department of Ophthalmology 
Royal Victorian Eye & Ear Hospital, 
32 Gisborne St, 
EAST MELBOURNE Vic 3002 
Ph & Fax 03) 9929 8713 
The glaucoma inheritance study is looking for families with glaucoma to find the genes that mice glaucoma We 
are inviting individuals and families who are afected with glaucoma to be involved in the study. This is at no cost to you. 
We wish to take a blood sample, or a mouth swab to test your DNA to see if we can find the mutations in the first gene that we 
have discovered that causes glaucoma If this first gene is not afected we may use the DNA to help discover the other genes 
that lead to glaucoma You are under no obligation to provide this and it may not cary any direct benefit to your glaucoma 
management, but it may assist us in understanding who else in your family is at risk of glaucoma 
The DNA wil be tested and we may find: A change in the DNA, no change in the DNA, or be unable to find 
anything. You wil be informed of the result of your test and be able to discuss this with us at any time. 
The DNA wil be stored at the Universities of Tasmania and Melbourne. The results of any scientific development 
wil be owned by the Universities of Tasmania and Melbourne and their colaborators. You may ask to withdraw from the 
study at any time, without prejudice, and have your sample destroyed. We may do further studies on glaucoma at a later date 
and wil of course inform you of your results. In our work we may find other abnormalities of the DNA and wil discuss the 
results with you. This study wil only be looking at genes related to glaucoma We may also find that you are distantly related 
to other families that we have studied, based on the DNA findings. These results may al be published but wil never identify 
you specificaly. 
We wil give you a copy of this form to keep for future reference. For more details or any questions please contact 
Dr David Mackey on the above numbers or leave a message. The study is conducted in accordance with the NHMRC 
guidelines for human genetic research. If you have any questions about the ethical nature of this study you may contact Dr 
Rosalie Parton of the RHH ethics commitee on 03)6222 8226. 
Please sign this form to certify that you read and understood the Information sheet, and had explained the nature 
and possible outcomes from the DNA testing and your questions have been answered to your satisfaction. 
Jam ;recopy to participate in the Glaucoma Inheritance Study GIST. 
Name 
Signed 	 Date 	 / 	/2005 
Witness Name 
Signed 	 Date 	 / 	/2005 
Address 
Researcher Statement: 	 I have explained the GIST project and its implications to this volunteer and I believe that the 
consent is informed and that he/she understands the implications of participation. 
Name: 
Signed 	 Date 	 / 	/2005 
APPENDIX B 
GIST Glaucoma Inheritance Study: 
Your Name 	 Place of Birth 
Spouses name 
Please answer the folowing to the best of your ability. Leave blank if unknown. 
Your father's name 	 date of birth  / / 	Place 	  
Your father's father's name 	 date of birth / / 	 Place 	  
Your father's mother's ful name 	 date of birth  / / 	Place 	  
(and maiden name) 
Your mother's 'name 	 date of birth  / / 	Place 	  
(and maiden name) 
Your mother's father's name 	 date of birth  / / 	Place 	  
Your mother's mother's ful name 	 date of birth 	 / / 	Place 	  
(and maiden name). 
Names of your brothers and sisters 	 date of birth 
(First and Surnames 
with maried names of sisters; 
please note if deceased. 
If insuficient space please 
use the reverse of this 
sheet or atach list) 
Names of your children 	 Their dates of birth 	  
Other Relatives afected with glaucoma (please note if deceased) 
Name 	 Relationship 	 Address 	  
Name 	 Relationship 	 Address 	  
Name 	 Relationship 	 Address 	  
Name 	 Relationship 	 Address 	  
Name 	 Relationship 	 Address 	  
Name 	 Relationship 	 Address 	  
Is anyone tracing the family tree? Name and Address 	  
Could you please atach or forward a copy of your family tree? 
Thank you for your help with the Glaucoma Inheritance Study. 
Glaucoma Inheritance Study 	 GIST 	 G 	 /Registry Bleed 
Please complete the folowing information to the best of your ability. If you do not know the answer please 
leave the question blank. 
Today's Date 	 / 	 / 	Time 	  
Surname 	  
Maiden Name 	 GP 	  
First Name 	 Ophthalmologist 	  
Address 	 Date of Birth 	 / 	 / 
Age 
	 Post Code 	  
Phone 	  
Do you have glaucoma? 
When was the date of Diagnosis? 	 Your age at Diagnosis? 	  
The highest eye pressure if known? 	  
Fathers side? 	 Yes/No 
Do you have a family history of glaucoma? Yes/No 	 Mothers side? Yes/No 
Number afected 
Please name your Glaucoma Medications 	  
Have you ever had eye surgery or laser treatments for glaucoma? 	  
What and When? 	  
Do you have any other eye problems? 	  
Have you had any other eye surgery? (What and When) 	  
or injury to your eyes? 	  
Are you on any general medications? 
Please name them if possible 	  
Do you have high blood pressure? 	 Yes/No 
Do you smoke? 	 Yes/No 
Do you have diabetes? 	 Yes/No 
Have you ever had a blood transfusion? 	 Yes/No 	 Why? 
Have you ever had a heart atack, stroke or any other disease with hardening of the arteries? 	 Yes/No 
Do you get cold hands or feet? 	 Yes/No 
Have you had any thyroid problems? 	 Yes/No 
Do you sufer from migraine headaches? 	 Yes/No 
Have you ever been on Cortisone or steroid medication? 	 Yes/No 
Predilation Exam: 	 Right 
Acuity: 
Refraction: 	 Distance 
and/or Readers 
IOP: 
Gonioscopy: 
Anterior Segment 
Left 	 Tick when dor 
Hx 
Cons 
Field 
Pres; 
Dila1 
Bloo 
Phot 
Let( 
Dilated Exam: No 1 	 Right 
Cup/Disc ratio 
Disc Size (S,M,L) 
Other Disease 	 0 
Score R 	 L 
Left 
0 
signature 
Stereophoto or Dilated Exam: No 2 Right 
Cup/Disc ratio 
Disc Size (S,M,L) 
Other Disease 	 0 
Score R 
Left 
0 
L 	 signature 
Stereophoto or Dilated Exam: No 3 Right 
Cup/Disc ratio 
Disc Size (S,M,L) 0 
Other Disease 
Score R 
Left 
0 
L 	 signature 
Field Score 	 Right 	 Left 
Reliability 
Score:A,B,C,D: 
GIST Field Score 
Concordance between field and discs? 	 Yes/No 
Glaucoma Type,Consistent with family's Type and other comments. 
Field Score 
Pressure Score 
Disc Score 	  
GIST SCORE. 
